Rubius Therapeutics is developing Red-Cell Therapeutics (RCTs) as a new treatment modality to address a wide array of indications including autoimmune, metabolic and other diseases. RCTs can have diverse biotherapeutic activities and are uniquely capable of engaging and stimulating or attenuating the immune system. The company has established a platform for the rapid design, generation, testing and development of RCT products. The company was founded and launched by Flagship VentureLabs, the innovation foundry of Flagship Ventures.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/09/15 | $25,000,000 |
Flagship Ventures | undisclosed | |
| 06/22/17 | $120,000,000 |
Flagship Pioneering | undisclosed | |
| 03/01/18 | $100,000,000 |
